Samsung Biologics has signed multiple contract manufacturing agreements with global pharmaceutical companies, surpassing 3 trillion won in annual cumulative orders in just five months.
On the 26th, Samsung Biologics announced through a disclosure that it has signed two contract manufacturing organizations (CMO) agreements totaling 440.5 billion won ($319.57 million) with pharmaceutical companies based in Europe and Asia.
The contracts are valued at 242 billion won ($175.55 million) with the European pharmaceutical company and 198.5 billion won ($144.03 million) with the Asian pharmaceutical company, each set to last until Dec. 31, 2030, and Dec. 31, 2033, respectively. The names of the clients and products were not disclosed due to confidentiality agreements.
This company has signed a total of four new contracts this year alone. Starting with its first contract in January, it has secured new orders globally from the United States, Asia, and Europe, recording 3.2525 trillion won in orders, surpassing 60% of last year's annual order amount (5.4035 trillion won) in just five months.
Since its inception, the cumulative order aggregates have exceeded approximately $18.2 billion (about 24.89 trillion won). Currently, 17 out of the top 20 global pharmaceutical companies are clients of this company.
Samsung Biologics is accelerating its efforts to expand production capacity to meet increasing demand for biopharmaceuticals. The fifth plant, a production facility with a capacity of 180,000 liters that incorporates the best practices of plants one through four, commenced full-scale operations in April. Through this, Samsung Biologics has secured the world's largest production capacity at a total of 784,000 liters. As of April this year, it has obtained 356 manufacturing approvals from major global regulatory agencies, including those in the United States, Europe, and Japan.
The company plans to strengthen its order activities further by participating in the world’s largest pharmaceutical and biotech expo, the 2025 BIO International Convention in Boston, USA, in June.